Estimated cut-off values for pemphigus severity classification according to pemphigus disease area index (PDAI), autoimmune bullous skin disorder intensity score (ABSIS), and anti-desmoglein 1 autoantibodies.

Q2 Medicine
Farnam Mohebi, Soheil Tavakolpour, Amir Teimourpour, Roja Toosi, Hamidreza Mahmoudi, Kamran Balighi, Narges Ghandi, Maryam Ghiasi, Pedram Nourmohammadpour, Vahideh Lajevardi, Robabeh Abedini, Armaghan Azizpour, Maryam Nasimi, Maryam Daneshpazhooh
{"title":"Estimated cut-off values for pemphigus severity classification according to pemphigus disease area index (PDAI), autoimmune bullous skin disorder intensity score (ABSIS), and anti-desmoglein 1 autoantibodies.","authors":"Farnam Mohebi, Soheil Tavakolpour, Amir Teimourpour, Roja Toosi, Hamidreza Mahmoudi, Kamran Balighi, Narges Ghandi, Maryam Ghiasi, Pedram Nourmohammadpour, Vahideh Lajevardi, Robabeh Abedini, Armaghan Azizpour, Maryam Nasimi, Maryam Daneshpazhooh","doi":"10.1186/s12895-020-00105-y","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Pemphigus is a potentially fatal disease if left untreated. Valid scoring systems and defined cut-off values for classification of patients would help with better management through specified pharmaceutical and non-pharmaceutical treatments.</p><p><strong>Methods: </strong>In this study, pemphigus patients who were receiving immunosuppressive treatments and had recent disease relapse were recruited for examination of pemphigus disease area index(PDAI), autoimmune bullous skin disorder intensity score (ABSIS), physician global assessment (PGA), autoimmune bullous disease quality of life (ABQoL), anti-desmoglein 1 (anti-Dsg1), and anti-Dsg3 autoantibody titers from December-2017 to February-2018. Cut-off values were estimated using model-based clustering classification and the 25th and 75th percentiles approach, performed separately for the exclusive cutaneous, exclusive mucosal, and mucocutaneous groups.</p><p><strong>Results: </strong>In the 109 included patients, the 25th and 75th percentiles cut-offs were 6.2 and 27 for PDAI score, and 4 and 29.5 for ABSIS score. The model-based analysis resulted in two groups (cut-point:15) for PDAI score, and three groups (cut-points:6.4 and 31.5) for ABSIS score. The groups were significantly different for the PDAI, ABSIS, PGA, and ABQoL values. Based on anti-Dsg1 autoantibody values, the model-based analysis cut-point was 128 and the 25th and 75th percentiles cut-offs were 98 and 182. Anti-Dsg3 autoantibody values did not differentiate between pemphigus severity classes.</p><p><strong>Conclusions: </strong>Estimated cut-off values based on the anti-Dsg1 level, PDAI, and ABSIS scoring systems could be used to classify patients into different severity grades for better management and prognosis.</p>","PeriodicalId":9014,"journal":{"name":"BMC Dermatology","volume":"20 1","pages":"13"},"PeriodicalIF":0.0000,"publicationDate":"2020-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7603731/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Dermatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s12895-020-00105-y","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Pemphigus is a potentially fatal disease if left untreated. Valid scoring systems and defined cut-off values for classification of patients would help with better management through specified pharmaceutical and non-pharmaceutical treatments.

Methods: In this study, pemphigus patients who were receiving immunosuppressive treatments and had recent disease relapse were recruited for examination of pemphigus disease area index(PDAI), autoimmune bullous skin disorder intensity score (ABSIS), physician global assessment (PGA), autoimmune bullous disease quality of life (ABQoL), anti-desmoglein 1 (anti-Dsg1), and anti-Dsg3 autoantibody titers from December-2017 to February-2018. Cut-off values were estimated using model-based clustering classification and the 25th and 75th percentiles approach, performed separately for the exclusive cutaneous, exclusive mucosal, and mucocutaneous groups.

Results: In the 109 included patients, the 25th and 75th percentiles cut-offs were 6.2 and 27 for PDAI score, and 4 and 29.5 for ABSIS score. The model-based analysis resulted in two groups (cut-point:15) for PDAI score, and three groups (cut-points:6.4 and 31.5) for ABSIS score. The groups were significantly different for the PDAI, ABSIS, PGA, and ABQoL values. Based on anti-Dsg1 autoantibody values, the model-based analysis cut-point was 128 and the 25th and 75th percentiles cut-offs were 98 and 182. Anti-Dsg3 autoantibody values did not differentiate between pemphigus severity classes.

Conclusions: Estimated cut-off values based on the anti-Dsg1 level, PDAI, and ABSIS scoring systems could be used to classify patients into different severity grades for better management and prognosis.

Abstract Image

Abstract Image

Abstract Image

根据丘疹性荨麻疹病区指数(PDAI)、自身免疫性大疱性皮肤病强度评分(ABSIS)和抗去疱疹素 1 自身抗体对丘疹性荨麻疹严重程度进行分类的估计临界值。
背景:丘疹性荨麻疹如不及时治疗可能会致命。采用有效的评分系统和明确的临界值对患者进行分类,有助于通过特定的药物和非药物治疗更好地控制病情:本研究招募了正在接受免疫抑制治疗且近期复发的丘疹性荨麻疹患者,于2017年12月至2018年2月期间对丘疹性荨麻疹病区指数(PDAI)、自身免疫性大疱性皮肤病强度评分(ABSIS)、医生总体评估(PGA)、自身免疫性大疱性皮肤病生活质量(ABQoL)、抗去疱疹素1(抗Dsg1)和抗Dsg3自身抗体滴度进行检测。采用基于模型的聚类分类法和第25百分位数和第75百分位数法估算临界值,分别用于专属皮肤组、专属粘膜组和粘膜皮肤组:在纳入的 109 例患者中,PDAI 评分的第 25 百分位数和第 75 百分位数临界值分别为 6.2 分和 27 分,ABSIS 评分的第 25 百分位数和第 75 百分位数临界值分别为 4 分和 29.5 分。基于模型的分析结果显示,PDAI 评分分为两组(切点:15),ABSIS 评分分为三组(切点:6.4 和 31.5)。各组的 PDAI、ABSIS、PGA 和 ABQoL 值均有明显差异。根据抗 Dsg1 自身抗体值,基于模型的分析切点为 128,第 25 和 75 百分位数切点分别为 98 和 182。抗Dsg3自身抗体值并不能区分丘疹性荨麻疹的严重程度:结论:基于抗-Dsg1水平、PDAI和ABSIS评分系统的估计临界值可用于将患者分为不同的严重程度等级,以便更好地管理和预后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
BMC Dermatology
BMC Dermatology Medicine-Dermatology
自引率
0.00%
发文量
0
期刊介绍: BMC Dermatology is an open access journal publishing original peer-reviewed research articles in all aspects of the prevention, diagnosis and management of skin disorders, as well as related molecular genetics, pathophysiology, and epidemiology. BMC Dermatology (ISSN 1471-5945) is indexed/tracked/covered by PubMed, MEDLINE, CAS, EMBASE, Scopus and Google Scholar.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信